-
Mashup Score: 0Oncology Drug Crash Course: Tucatinib and Trastuzumab for HER2+ CRC - 10 month(s) ago
Tucatinib was first approved by the FDA for the treatment of patients with HER2-positive advanced unresectable or metastatic breast cancer in combination with trastuzumab and capecitabine on April 17, 2020.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Oncology Drug Crash Course: Tucatinib and Trastuzumab for HER2+ CRC - 10 month(s) ago
Tucatinib was first approved by the FDA for the treatment of patients with HER2-positive advanced unresectable or metastatic breast cancer in combination with trastuzumab and capecitabine on April 17, 2020.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Oncology Drug Crash Course: Tucatinib and Trastuzumab for HER2+ CRC - 10 month(s) ago
Tucatinib was first approved by the FDA for the treatment of patients with HER2-positive advanced unresectable or metastatic breast cancer in combination with trastuzumab and capecitabine on April 17, 2020.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Lindsay Diamond, MSN, AGNP-C, AOCNP, discusses findings from CheckMate 274 and other data presented during the 2023 ASCO Genitourinary Cancers Symposium.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Lindsay Diamond, MSN, AGNP-C, AOCNP, discusses findings from CheckMate 274 and other data presented during the 2023 ASCO Genitourinary Cancers Symposium.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Listen to Lindsay Diamond, MSN, AGNP-C, AOCNP, discuss findings from CheckMate 274 and other data presented during the 2023 ASCO Genitourinary Cancers Symposium. #blcsm #bladdercancer #Oncologynursing #nursepractitioner #GU23 #immunotherapy @TischCancer https://t.co/kWOocPx2rA https://t.co/NZbkfAiV0M
-
-
Mashup Score: 1
Lindsay Diamond, MSN, AGNP-C, AOCNP, discusses findings from CheckMate 274 and other data presented during the 2023 ASCO Genitourinary Cancers Symposium.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Pollack Discusses Ongoing Research for Patients With Refractory mCRC and Other Hard-to-Treat GI Malignancies - 1 year(s) ago
Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, discusses key data that may affect clinical practice for nurses from the 2023 GI Cancers Symposium.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Oncology Drug Crash Course: Tucatinib and Trastuzumab for HER2+ CRC. #oncology #nursing #crcsm #nursepractitioner https://t.co/1Rxvmo5bXa